

Estimation of Salivary IL-6 and Calprotectin in Patients with Ulcerative Colitis

Fadhel A. Abed*¹ , Maha A. Mahmood¹ 

¹ Department of Basic Sciences, College of Dentistry, University of Baghdad, Baghdad, Iraq.



©2024 The Author(s). Published by College of Medicine, University of Baghdad. This open-access article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Inflammatory bowel disease is a chronic inflammatory condition affecting the gastrointestinal tract, encompassing two primary conditions: Crohn's disease and ulcerative colitis. Calprotectin, a protein released by keratinocytes, phagocytes, monocytes, granulocytes, and vascular cells, plays a key role in the body's inflammatory response. It is recognized by toll-like receptors, which trigger pathways that lead to inflammation. The chronic nature of inflammatory bowel disease presents a significant health challenge, requiring precise methods for regular assessment and monitoring of disease activity. Elevated calprotectin levels are widely recognized as a biomarker for detecting inflammation in the gastrointestinal tract, making it an essential tool in managing inflammatory bowel disease, particularly ulcerative colitis.

Objectives: To examine whether significant differences exist in the levels of interleukin-6 and calprotectin between patients with ulcerative colitis and healthy control subjects, this study analyzes and compares these inflammatory markers across both groups. suggesting that both markers could serve as potential diagnostic tools for ulcerative colitis. Furthermore, these findings highlight saliva as a non-invasive source for evaluating inflammatory markers in patients with ulcerative colitis.

Methods: The subjects included were twenty-five patients with ulcerative colitis and twenty-five healthy individuals as the control group. All of whom ranged in age from 20-55 years, and the levels of interleukin-6 (IL-6) and calprotectin in the saliva of ulcerative colitis patients were measured using the ELISA method.

Results: When compared to the control group, the current findings indicated that both (IL-6) and calprotectin levels were significantly higher in UC patients. Moreover, this study found a significant positive correlation between IL-6 levels and age in all study groups (UC and control) and between IL-6 and calprotectin in UC patients.

Conclusion: There are higher levels of IL-6 and calprotectin in the saliva of patients with UC disease, both markers could be used as diagnostic markers for UC disease

Keywords: Calprotectin; Inflammatory Bowel Diseases; Interleukin-6; Saliva and Ulcerative Colitis

Received: Feb. 2023
Revised: Jan. 2023
Accepted: Aug. 2023
Published: Dec. 2024

Introduction:

A chronic inflammatory ailment called inflammatory bowel disease (IBD) has been linked to cytokines in terms of its pathophysiology and etiology. Ulcerative colitis (UC) and Crohn's disease (CD) are the two most prevalent clinical forms of IBD (1). In people with a genetic predisposition to IBD, leads to inflammation and intestinal ulcers (2). There are numerous Therapeutic options available for the idiopathic chronic inflammatory disease of the colon known as ulcerative colitis (3).

One type of inflammatory bowel illness that affects the colon and the rectum is ulcerative colitis. Rarely does it affect infants and young children (4). It is still unclear what causes ulcerative colitis and how it develops. The notion that a genetic element is key in the progression of the disease, however, has received attention (5). The incidence has increased in nations that have adopted an industrialized lifestyle, which refers to regions where steps have been done to

enhance the state of health globally, such as vaccination, gastrointestinal disease prevention, processed foods, etc. Exacerbations can be life-threatening and come with problems. Severe UC is diagnosed based on clinical, biochemical, and endoscopic findings Serious UC patients need to be hospitalized (6). Interleukin-6 (IL-6) is produced in acute inflammatory responses that aid in host defense. It is involved in the processes of immune response regulation, inflammation, hematopoiesis, and cancer (7). Immune responses may be disrupted if IL-6 levels are elevated as IL-6 is involved in the regulation of lymphocyte tracking through the lymph node following developmental stimulation (7). It was stated that IL-6 promotes the change from severe to chronic inflammation by secreting the monocytes chemo-attractant protein-1 (MCP-1) (8). IL-6 and TNF are regarded as the two main mediators of the inflammatory process. These cytokines have systemic effects that include raised body temperature, enhanced lymphocyte activation, and neutrophil mobilization (9).

* Corresponding author:
fadel.abdullah1200a@codental.uobaghdad.edu.iq

It was concluded that patients with IBD have significantly elevated levels of IL-6 in their plasma (10). Calprotectin is generated by phagocytes, keratinocytes, granulocytes, monocytes, and vascular cells and causes an inflammatory (11). Calprotectin, also known as the migration inhibitory factor-related proteins 8 and 14, is an acute-phase protein that regulates neutrophil migration; its quantity corresponds with neutrophil migration and indicates the intensity of inflammation in IBD. Calprotectin levels in saliva could be employed as a predictive diagnostic as well as a measure of treatment efficacy. However, doctors must keep in mind that oral inflammation, obesity, oral candidiasis, and periodontal disease all have an impact on calprotectin secretion (12,13).

This study aimed to measure IL-6 and calprotectin levels in the saliva of UC patients as those cytokines have been previously proven to be elevated in sera of UC patients but have not been proved yet to be increased in saliva.

Materials and Methods:

Four milliliters of unstimulated saliva were taken from twenty-five (UC) patients and twenty-five healthy controls. For the purpose of performing the salivary analysis of IL-6 and calprotectin, the saliva samples were centrifuged for 10 minutes at 3500 rpm/min, and the supernatant was divided into two Eppendorf tubes and kept at -70°C. Commercial ELISA kits for human IL-6 and calprotectin (USA) were used to measure the salivary levels of each marker according to the manufacturer's instructions using a micro-plate reader and the absorbance was measured at a wavelength of 450 nm (Huma Reader HS, Germany).

Statistical analysis:

The statistical analysis was done in two categories:

Descriptive analysis, in which data was presented as minimum, maximum, mean, and standard deviation (SD) for quantitative variables, and frequency for qualitative variables. And inferential analysis: Inferential analysis was used to clarify valuable insights about the differences and relationships between different variables in the study community. We used parametric statistical analysis. This type of analysis is employed when dealing with continuous data and assumes that the data follows a normal distribution. The statistical tests used in the tables are the F-test, correlation coefficients, the chi-square test, or Fisher's exact test, as indicated by the p-values and independent t-tests.

Results:

The mean and standard deviations for the age of patients with UC and healthy people have the following comparable values (33.400 ± 1.0905 , 30.280 ± 0.6321 ng/ml), respectively, with no significant differences seen between both groups ($P > 0.05$) as presented in table (1).

Table (1): Distribution of study UC according to age

| Group | Age (years) | | | | |
|---------|-------------|----------|----------|------|------|
| | NO | Mean | S.D. | Min. | Max. |
| Control | 25 | 30.280 | 0.6321 | 23 | 48 |
| UC | 25 | 33.400 Y | 1.0905 Y | 20 Y | 55 Y |

(p-value UC = 0.46) (P-value control= 0.46)

The results in table (2) shown that UC patients have percentages of 48% and 52% for males and females, respectively, and the control group matches the patients' group as it has percentages of 60% for males and 40% for females with no significant difference has been observed between them ($P > 0.05$).

Table (2): Distribution of subjects according to gender

| Gender | Control | UC |
|---------|-----------|-----------|
| Males | 15 (60%) | 12 (48%) |
| Females | 10 (40%) | 13 (52%) |
| Total | 25 (100%) | 25 (100%) |

(p-value UC = 0.46) (p-value control = 0.46).

The mean levels of salivary interleukin-6 and calprotectin showed a higher concentration with a significant difference in the ulcerative colitis group when compared with the healthy controls ($p < 0.05$) as seen in Tables 3 & 4.

Table (3): The mean levels of IL6 and calprotectin in study groups

| Parameter | Group | No | Mean | S. D. | S.E | Min. | Max. | p values |
|--------------------|---------|----|---------|--------|--------|---------|---------|----------|
| Calprotectin ng/ml | Control | 25 | 169.800 | 18.867 | 3.773 | 132.784 | 198.777 | 0.000 |
| | UC | 25 | 241.871 | 6.830 | 13.660 | 135.592 | 378.897 | |
| IL-6 pg/ml | Control | 25 | 53.509 | 8.996 | 1.799 | 33.291 | 65.609 | 0.000 |
| | UC | 25 | 85.537 | 3.004 | 6.009 | 43.864 | 166.048 | |

Table (4): A comparative F-test for IL-6 and calprotectin levels among the study groups

| Parameter | | Sum of Squares | d.f. | Mean Square | F-test | p-value |
|--------------|----------------|----------------|------|-------------|--------|---------|
| Calprotectin | Between Groups | 140327.097 | 2 | 70163.548 | 15.991 | 0.000 |
| | Within Groups | 315915.556 | 47 | 4387.716 | | |
| | Total | 456242.653 | 49 | | | |
| IL-6 | Between Groups | 20867.773 | 2 | 10433.886 | 21.100 | 0.000 |
| | Within Groups | 35603.598 | 47 | 494.494 | | |
| | Total | 56471.371 | 49 | | | |

Furthermore, the correlation between IL-6 and each of calprotectin and age in ulcerative colitis patients was positive and statistically significant as correlation coefficient values were ($r=0.614$ and $r=0.405$), respectively, ($P < 0.01$) as shown in (Table 5).

Table (5): Correlation coefficient of IL-6 with calprotectin and age in ulcerative colitis patients

| UC | | |
|--------------|--------------|--------|
| Parameter | Calprotectin | IL-6 |
| Age | r | -0.282 |
| | P | 0.172 |
| Calprotectin | r | 0.614 |
| | P | 0.001 |

The correlation coefficient between IL-6 and calprotectin in healthy control group was positive non-significant correlation ($P > 0.05$) but the correlation between IL-6 and age was a significantly positive ($r = 0.421$) ($p < 0.05$) as shown in table (6).

Table (6): Correlation coefficient of IL-6 with calprotectin and age in control group

| Control | | |
|--------------|--------------|-------|
| Parameter | Calprotectin | IL-6 |
| Age | r | 0.017 |
| | P | 0.936 |
| Calprotectin | r | 0.289 |
| | P | 0.161 |

Discussion:

Furthermore, this work showed no significant differences in exposure rate to UC between both genders ($p > 0.05$) whereas an epidemiological survey from East Asian countries notably Japan and China showed lower incidence in females than males (28). According to data from twelve Asian-Pacific countries, it was demonstrated a male predominance of UC from adolescence till age of 65 years, after which UC incidence rates were similar between females and males (30).

The ages of UC patients in present study ranged from 20-55 years with a mean value of 33.4 ± 1.09 years. Similarly, the results of Nijakowski et al (2021) that was carried out in 2021 showed that the UC group has an age range between 24 -40.5 years with a mean age value of 32 years. Also, comparable results were seen by a cross-sectional study conducted at the Kurdistan center for gastroenterology and hepatology of the teaching hospital in Sulaymaniyah, Iraq, which included 101 patients who had previously been diagnosed with inflammatory bowel disease that showed that UC patients have a mean age value of 45.74 years (16, 17). In general, females and males showed similar incidence of UC before age 45; however, above age 45 years, males demonstrated higher risk of UC incidence than females (29).

This study selected saliva collection as a straightforward and non-invasive approach for UC patients. It was observed that there was a statistically significant difference in salivary IL-6 levels between UC patients and the control group whereas other studies have also revealed that unstimulated saliva of

IBD patients has higher levels of IL-6 (32). Other studies have previously demonstrated that IL-6 levels are increased in patients with inflamed, non-adhesive intestinal mucosa of IBD (33).

The patients with UC had higher IL-6 concentrations in their saliva. Because the cells that produce saliva are components of the digestive system, this may suggest that the inflammatory process in the intestine induces a significant release of IL-6 in the saliva (22). Another study illustrated that the activity of IBD might be estimated from the levels in saliva as well as plasma in UC patients (23).

After thorough validation of our analytical methods and protocol, the current study compared calprotectin levels in unstimulated saliva from UC patients with ongoing intestinal inflammation to controls. The calprotectin levels were substantially higher in UC patients' saliva than the control group. The findings of this investigation have been supported by another previous study which also observed significantly elevated levels of calprotectin in saliva of patients with ulcerative colitis as compared with control group (24).

Calprotectin is mostly present in neutrophils and, to a lesser extent, in other cells, calcium-binding protein in reactive macrophages and monocytes (25). Plasma calprotectin has been reported to increase 5- to 40-fold in inflammatory and infectious circumstances, and it has bacteriostatic and fungi-static characteristics. Stool contains calprotectin, and fecal calprotectin concentration is approximately six times that of normal plasma. Patients with intestinal irritation had feces with noticeably higher amounts of calprotectin (26).

This is the first study that evaluated calprotectin level in saliva. It was noted that calprotectin had a significant higher levels in UC group when compared with control group whereas previous researchers looked at calprotectin in feces and proved that fecal calprotectin levels in gastrointestinal disorders, such as gastritis, gastric ulcer, gastric carcinoma, duodenitis, ulcerative colitis, have significantly higher levels than the controls (27). Compared to the control group, the concentrations of calprotectin and myeloperoxidase in saliva were significantly lower both in CD patients and in UC patients (31).

Conclusion:

This study concluded that levels of interleukin-6 and calprotectin in saliva are higher in patients with ulcerative colitis compared to healthy individuals (control group), suggesting that both markers could serve as potential diagnostic tools for ulcerative colitis. Furthermore, these findings highlight saliva as a non-invasive source for evaluating inflammatory markers in patients with ulcerative colitis. Further research is recommended to explore the relationship between these marker levels and disease progression, which may enhance patient care and guide therapeutic strategies.

Authors' Declaration:

We hereby confirm that all the Figures and Tables in the manuscript are ours. The project was approved by the local ethical committee in College of Dentistry/ University of Baghdad, Iraq.

Conflicts of Interest: None

Funding source: None

Authors' Contributions:

Study conception & design: (Maha A. Mahmood). Literature search, Data acquisition, Data analysis, interpretation & Manuscript preparation: (Fadhel A. Abed). Manuscript editing & review: (Maha A. Mahmood).

Reference

1. Abdul-Hussein SS, et al. Roles of IL-17A and IL-23 in the Pathogenesis of Ulcerative Colitis and Crohn's Disease. *Iraqi Journal of Science*. 2021; 2526-2535. <https://doi.org/10.24996/ijs.2021.62.8.5>.
2. Frøslie KF, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology*. 2007; 133(2): 412-422. <https://doi.org/10.1053/j.gastro.2007.05.05>.
3. Manna MJ, Abu-Raghif A, Al-Saree OJAH. The value of doxycycline in acetic acid induce ulcerative colitis in rats. *IJPSR*. 2018; 9(8): 3567-3572. [http://dx.doi.org/10.13040/IJPSR.0975-8232.9\(8\).3567-72](http://dx.doi.org/10.13040/IJPSR.0975-8232.9(8).3567-72).
4. Abdal-Zahra N, et al. The significance of miR-196a2 C < T single nucleotide polymorphism and serum levels of interleukin-1 β (IL-1 β) and interleukin-6 (IL-6) in colorectal cancer. *JPharmSciRes*. 2019; 11(4): 1652-165. <https://doi.org/10.1016/j.mgene.2017.02.004>.
5. Al-Hassan AA. Possible association of HLA class I and II molecules with Ulcerative colitis in Iraqi patients. *Iraqi Journal of Medical Sciences*. 2008; 6 (1). <https://www.iasj.net/iasj/download/4cde74b676b80148>
6. Daham KJ, Hamel KI, Khorsheed SA. Management of ulcerative colitis in a sample of Iraqi patients. *International Journal of Surgery*. 2019; 3(3):344-348. <https://doi.org/10.33545/surgery.2019.v3.i3f.192>.
7. Surcel M, et al. Inflammatory cytokine pattern is sex-dependent in mouse cutaneous melanoma experimental model. *Journal of Immunology Research*. 2017; 2017. <https://doi.org/10.1155/2017/9212134>.
8. Gabay C. Interleukin-6 and chronic inflammation. *Arthritis research & therapy*. 2006; 8(2): 1-6. <https://doi.org/10.1186/ar1917>
9. Juda TM. Salivary Interleukin 6 and its role in developing periodontitis. *Iraqi National Journal of Chemistry*. 2016; 16(1).
10. Larsen TB, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. *Pathophysiology of Haemostasis and Thrombosis*. 2002; 32(2): 92-96. <https://doi.org/10.1159/000065082>.
11. Al-Tameemi S, et al. Calprotectin may be positively associated with the severity of acne vulgaris. *Baghdad Journal of Biochemistry and Applied Biological Sciences*. 2022; 3(02): 145-155. <https://doi.org/10.47419/bjbabs.v3i02.124>.
12. Wei L, Liu M, Xiong H. Role of calprotectin as a biomarker in periodontal disease. *Mediators of Inflammation*. 2019; 2019. <https://doi.org/10.1155/2019/3515026>.
13. Ostrowska L, et al. Which salivary components can differentiate metabolic obesity?. *PLoS One*. 2020; 15 (6): e0235358. <https://doi.org/10.1371/journal.pone.0235358>.
14. Gilat D. The best bound in the $\square\square\square\square$ inequality of Hardy and Littlewood and its martingale counterpart. *Proceedings of the American Mathematical Society*. 1986; 97(3): 429-436. <https://doi.org/10.1090/s0002-9939-1986-0840624-3>.
15. Hassan JT, et al. Epidemiological and clinical characteristics of patients with inflammatory bowel disease in Erbil City. *MJB*. 2018; 15(4): 281. https://doi.org/10.4103/mjbl.mjbl_65_18.
16. Hammasur GA, Mohammed FO, Ahmad AJ. Assessment of rock slope stability along Sulaimaniyah-Qaradagh main road, near Dararash Village, Sulaimaniyah, NE-Iraq. *Iraqi Journal of Science*. 2020; 3266-3286. <https://doi.org/10.24996/ijs.2020.61.12.15>.
17. Hirano T. Interleukin 6 and its receptor: ten years later. *International Reviews of Immunology*. 1998; 16(3-4): 249-284. <https://doi.org/10.3109/08830189809042997>.
18. Atreya R, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. *Nature Medicine*. 2000; 6(5): 583-588. <https://doi.org/10.1038/75068>.
19. Baumann H, Gauldie J. The acute phase response. *Immunology Today*. 1994; 15(2): 74-80. [https://doi.org/10.1016/0167-5699\(94\)90137-6](https://doi.org/10.1016/0167-5699(94)90137-6).
20. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. *Gut*. 1994; 35(1): 77-83. <https://doi.org/10.1136/gut.35.1.77>.
21. Nielsen AA, et al. Saliva interleukin-6 in patients with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*. 2005; 40(12): 1444-1448. <https://doi.org/10.1080/00365520510023774>.
22. Al-Mudhaffer MH, Abdul-Ghafoor SH. Salivary assessment of interleukin-6, C-reactive protein, and albumin in ulcerative colitis patients in relation to oral findings. *Journal of Baghdad College of Dentistry*. 2013; 325(2204): 1-5. <https://doi.org/10.12816/0014972>.
23. Majster M, Almer S, Boström EA. Salivary calprotectin is elevated in patients with active inflammatory bowel disease. *Archives of Oral*

- Biology. 2019; 107: 104528. <https://doi.org/10.1016/j.archoralbio.2019.104528>.
24. Bjerke K, et al. Distribution of macrophages and granulocytes expressing LI protein (Calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. *Gut*. 1993; 34(10): 1357-1363. <https://doi.org/10.1136/gut.34.10.1357>.
25. Fagerberg UL, et al. Fecal Calprotectin levels in healthy children studied with an improved assay. *Journal of Pediatric Gastroenterology and Nutrition*. 2003; 37(4): 468-472. <https://doi.org/10.1097/00005176-200310000-00013>.
26. Burak S, Margat J. Water management in the Mediterranean region: concepts and policies. *Water Resources Management*. 2016; 30(15): 5779-5797. <https://doi.org/10.1007/s11269-016-1389-4>.
27. Zhou HJ, et al. Validation of the functional assessment of cancer therapy-gastric module for the Chinese population. *Health and Quality of Life Outcomes*. 2012; 10(1): 1-8.
28. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. *Gastroenterology*. 2018; 155: 1079-1089. <https://doi.org/10.1053/j.gastro.2018.09.014>.
29. Shah SC, Khalili H, Chen CY, et al. Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. *Aliment Pharmacol Ther*. 2019; 49: 904-911. <https://doi.org/10.1111/apt.15178>.
30. Nijakowski K, Surdacka A. Salivary Biomarkers for Diagnosis of Inflammatory Bowel Diseases: A Systematic Review. *Int J Mol Sci*. 2020. <https://doi.org/10.3390/ijms21207477>.
31. Nijakowski K, Surdacka A. Salivary Biomarkers for Diagnosis of Inflammatory Bowel Diseases: A Systematic Review. *Int J Mol Sci*. 2020; 21:7477. <https://doi.org/10.3390/ijms21207477>.
32. Szczeklik K, Owczarek D, Pytko-Polónczyk J, Kęsek B, Mach TH. Proinflammatory Cytokines in the Saliva of Patients with Active and Non-Active Crohn's Disease. *Pol Arch Med Wewn*. 2012; 122:200-208. <https://doi.org/10.20452/pamw.1256>.
33. Dobre M, et al. Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colitis. *Journal of Immunology Research*. 2018. <https://doi.org/10.1155/2018/9208274>.

How to Cite this Article

Abdullah Abdullah FA, A. Mahmood M. Estimation of Salivary IL-6 and Calprotectin in Patients with Ulcerative Colitis. *J Fac Med Baghdad*. 2024;66(4):419-24. Available from: <https://ijmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2031>

تقدير الإنترلوكين العابي 6 وكالبروتكتين في مرضى التهاب القولون التقرحي

فاضل عبد الله عبيد¹، مها عادل محمود¹
 افرع العلوم الأساسية، كلية طب الاسنان، جامعة بغداد، بغداد، العراق.

الخلاصة

مرض التهاب الأمعاء هو التهاب مزمن في الجهاز الهضمي ويشمل مرض كرون و التهاب القولون التقرحي ، وقد يتسبب الالتهاب لفترات طويلة في غزو الطبقات المتعددة من جدران الأمعاء مما يؤدي إلى تلف الجهاز الهضمي.

الهدف: أجريت الدراسة الحالية من أجل توضيح ما إذا كانت العلامة التشخيصية لـ IBD وهي IL6 و calprotectin ترتفع في اللعاب كما هو الحال في الأمصال وما إذا كانت هناك فروق ذات دلالة إحصائية في المستويات من تلك العلامات بين مرضى التهاب القولون التقرحي وموضوعات المراقبة الصحية.

طريقة البحث: أجريت الدراسة الحالية في مستشفى بغداد التعليمي ومستشفى أمراض الجهاز الهضمي من تشرين الثاني (نوفمبر) 2021 إلى أيار (مايو) 2022. شملت الدراسة خمسة وعشرين مريضاً يعانون من التهاب القولون التقرحي وخمسة وعشرون من الأفراد الأصحاء يمثلون المجموعة الضابطة. تراوحت أعمار كل منهم بين 20-55 سنة. تم قياس مستويات calprotectin و Interleukin-6 في لعاب مرضى التهاب القولون التقرحي UC باستخدام طريقة ELISA في الدراسة الإحصائية تم إجراء التحليل الإحصائي على فئتين: التحليل الوصفي: تم تقديم البيانات على أنها الحد الأدنى والحد الأقصى والمتوسط والانحراف المعياري (SD) للمتغيرات الكمية وتكرار المتغيرات النوعية. والتحليل الاستنتاجي: تم استخدام التحليل الاستدلالي لتوضيح رؤية قيمة حول الاختلافات والعلاقات بين المتغيرات المختلفة في مجتمع الدراسة. استخدمنا التحليل الإحصائي البارامترية. يتم استخدام هذا النوع من التحليل عند التعامل مع البيانات المستمرة ويفترض أن البيانات تتبع التوزيع الطبيعي. الاختبارات الإحصائية المستخدمة في الجداول هي اختبار F ، ومعاملات الارتباط ، واختبار مربع كاي ، أو اختبار فيشر الدقيق ، كما يوضح من قيم p واختبارات t المستقلة.

النتائج: عند المقارنة بمجموعة التحكم ، أشارت النتائج الحالية إلى أن كلا من (IL-6) ومستويات calprotectin كانت أعلى بشكل ملحوظ في مرضى التهاب القولون التقرحي ($P = <0.05$). علاوة على ذلك ، وجدت هذه الدراسة ارتباطاً إيجابياً معنوياً بين مستويات IL-6 والعمر في جميع مجموعات الدراسة (التهاب القولون التقرحي والتحكم) ($P < 0.05$).

الاستنتاج: وبين IL-6 و calprotectin في مرضى التهاب القولون التقرحي ($P < 0.05$) خلاصت هذه الدراسة إلى أن هناك مستويات أعلى من IL-6 و calprotectin في لعاب المرضى الذين يعانون من مرض UC مقارنة بالأشخاص الأصحاء مجموعة التحكم) ونتيجة لذلك ، يمكن استخدام كلا الواسميتين كواسمات تشخيصية لمرض UC.

الكلمات المفتاحية: إنترلوكين 6، كالبروتكتين ، مرضى التهاب القولون التقرحي.